Dupilumab

• UNSPSC Description:

  Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis[1].

• Target Antigen:

  Interleukin Related

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dupilumab.html

• Purity:

  99.20

• Solubility:

  H2O

• Smiles:

  [Dupilumab]

• References & Citations:

  [1]Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Store at 4°C for 2 years, do not freeze

• Clinical Information:

  Launched

• CAS Number:

  1190264-60-8